284 results about "Eye disease" patented technology

Provided in the present invention are a TSHR antagonist compound, a pharmaceutical composition, and a preparation method therefor and the use thereof. The compound has good TSHR antagonism, and is used in the treatment of thyroid-associated conditions and / or diseases, such as hyperthyroidism, Graves' disease, Graves' ophthalmopathy, and thyroid eye disease, and in the preparation of a drug for treating such conditions or diseases.

The invention belongs to the technical field of nano-drugs, and discloses a multifunctional nano-drug delivery system for treating neovascular eye diseases and a preparation method of the multifunctional nano-drug delivery system. The nano drug delivery system disclosed by the invention is a composite nano preparation which takes dendritic mesoporous silica nanoparticles as a carrier and co-loads cerium zirconium oxide nano enzyme and an anti-VEGF (vascular endothelial growth factor) drug, various active oxygen can be efficiently removed, oxygen is continuously released through catalytic decomposition of hydrogen peroxide, a retina hypoxia microenvironment is improved, and the retina hypoxia effect is improved. According to the present invention, the anti-VEGF drug delivery system can reduce the oxidative stress induced retinal pigment epithelial cell apoptosis rate, reduce the inflammatory reaction, and simultaneously achieve the slow release and the controlled release of the anti-VEGF drug, and the drug effect maintenance time can achieve more than 60 days, such that the multi-target synergistic treatment can be achieved through the synergistic regulation of the multiple pathological links such as oxygen deficit-oxidative stress-inflammation-angiogenesis, and the anti-VEGF drug delivery effect can be achieved. The choroidal neovascularization can be effectively inhibited by single intravitreal injection, and a new strategy of multi-target collaborative treatment is provided for neovascular macular degeneration and other eye diseases.

The present invention relates to methods for treating or reducing the severity of thyroid eye disease. In particular, the present invention provides methods for treating or reducing the severity of thyroid eye disease in patients in need thereof comprising administering an IGF-1R antagonist antibody according to specific dosage regimens. Pharmaceutical compositions comprising the IGF-1R antagonist antibody for use in the methods are also described.

The invention provides a thyroid-related eye disease intraorbital soft tissue volume measurement method and system, and is applied to the technical field of data processing. Three-dimensional medical image data and system abnormal state information are obtained, the three-dimensional medical image data comprise CT images and MRI images, and the system abnormal state information comprises artifacts, isolated noisy points and irregular boundaries; data preprocessing is carried out on the three-dimensional medical image data, standardized image data is generated, and the standardized image data is formed by carrying out ternary processing on spatial registration, noise suppression and gray level normalization; processing the standardized image data and the system abnormal state information to generate an initial segmentation mask; processing the initial segmentation mask to generate an optimized mask; processing the optimized mask and the three-dimensional medical image data to generate soft tissue volume data; and processing the soft tissue volume data, the system abnormal state information and the historical volume data to generate a volume dynamic change report.

Transcorneal and fiberoptic laser delivery systems and methods for the treatment of eye diseases wherein energy is delivered by wavelengths transparent to the cornea to effect target tissues in the eye for the control of intraocular pressure in diseases such as glaucoma by delivery systems both external to and within ocular tissues. External delivery may be affected under gonioscopic control. Internal delivery may be controlled endoscopically or fiberoptically, both systems utilizing femtosecond laser energy to excise ocular tissue. The femtosecond light energy is delivered to the target tissues to be treated to effect precisely controlled photodisruption to enable portals for the outflow of aqueous fluid in the case of glaucoma in a manner which minimizes target tissue healing responses, inflammation and scarring.

The invention relates to the technical field of medical instruments, in particular to a cornea protection eyeshade for a patient with hyperthyroidism eye disease, which comprises an eyeshade main body, the eyeshade main body comprises a support frame, a protection cover and a fitting layer are mounted on two sides of the support frame, and a self-adaptive fitting adjusting assembly, a multifunctional linkage module and a magnetic suction buffer assembly are further mounted on the support frame. The self-adaptive fitting adjusting assembly is used for driving the fitting layer to adapt to eye contours of different patients, the multifunctional linkage module is used for achieving switching of eye moisturizing and one-way light transmission of the patients, the magnetic attraction buffering assembly is used for relieving compression during wearing and fixing, and the monitoring assembly is installed on the fitting layer and used for monitoring state information of the eye contours of the patients. The monitoring assembly is in signal connection with a controller, and the controller is used for manually adjusting the moisturizing amount and the light transmission mode of the multifunctional linkage module according to the state information. According to the method, full-scene and personalized cornea protection is provided for a patient with hyperthyroidism synophthalmia, and the cornea is prevented from being damaged by exposure, dryness, strong light or compression.

The invention provides a method of treating or reducing the severity of thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), or a symptom or aspect thereof, in subjects that have undergone prior treatment for TAO, TED, or GO, and either did not respond to said prior treatment or relapsed after said prior treatment. The invention also provides antibodies, or antigen binding fragments thereof, and pharmaceutical compositions useful in the disclosed methods.

The invention provides a three-dimensional medical image segmentation method and system for thyroid-related eye diseases, and is applied to the technical field of data processing. Multi-modal medical image data, a coarse-grained segmentation result and a fine-grained segmentation result are obtained, the multi-modal medical image data comprise a CT image and an MRI image, the multi-modal medical image data are preprocessed, a fused image body is generated, and the fused image body is formed by registration and feature fusion of the CT image and the MRI image; processing the fused image body and the coarse-grained segmentation result to generate a fine segmentation result; processing the fine segmentation result to generate a preliminary segmentation mask; processing the preliminary segmentation mask and the multi-modal medical image data to generate a mixed loss function; and processing the preliminary segmentation mask, the mixed loss function and the extraocular muscle attachment point position based on a dynamic post-processing strategy to generate a final segmentation result.

Provided herein are methods of treating or reducing the severity of thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy (TAO), or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.

The invention discloses a continuous optical zoom slit-lamp microscope system and an inspection method and application thereof, and belongs to the technical field of ophthalmology medical equipment. The system is composed of a continuous zooming module, a light source module, a data processing module, a 3D imaging module and an AI identification module. The inspection method comprises the steps of equipment initialization and head position fixation of an inspected person, AI low-magnification (5 *) preliminary screening, adaptive lens high-magnification (40 *) fine observation, dynamic light source adjustment, three-dimensional data acquisition and cloud intelligent diagnosis. The method is applied to examination and intelligent diagnosis of eye diseases such as cataract. The problems that a traditional slit-lamp microscope is discontinuous in zooming, inconvenient to operate, lack of intelligent diagnosis and free of 3D stereoscopic display are solved, and the objective of the invention is to realize simple and convenient equipment operation, continuous examination process, intelligent diagnosis and stereoscopic display, facilitate collective teaching, significantly improve the diagnosis efficiency and accuracy of eye diseases such as cataract and the like, and improve the diagnosis efficiency and accuracy of eye diseases such as cataract and the like. And DICOM standard data cloud sharing and remote consultation are supported.

The invention discloses a thyroid eye disease activity evaluation method and system based on an eye image, and aims to solve the problems that the existing clinical activity score cannot reflect continuous change of an illness state and is susceptible to subjective influence. The method comprises the following steps: acquiring original image data containing an eye region; performing standardized preprocessing on the image data; extracting multi-scale inflammatory features and structural features from the preprocessed image; carrying out cross-modal fusion on the extracted multi-scale features; calculating an activity quantitative score based on the fused comprehensive features; and outputting a visual report of the quantitative score and the evaluation conclusion. The system comprises an image acquisition module, an image preprocessing module, a feature extraction module, a feature fusion module, an activity evaluation module and a result output module. According to the technical scheme, objective quantitative evaluation of thyroid eye disease activity can be achieved, the consistency and repeatability of evaluation results are improved, remote image acquisition and automatic analysis are supported, and the space-time limitation of traditional clinical evaluation is broken through.

The present application relates to an ophthalmic preparation and use thereof. Specifically, the present application relates to an ophthalmic preparation of pilocarpine and use thereof for treating eye diseases. The ophthalmic preparation of pilocarpine provided by the present application has the beneficial effects of good stability and less eye irritation.

An implant device for an eye disease to be inserted into an eyeball may include: a tube having one end to be inserted into an anterior chamber of the eyeball, the tube comprising a hollow portion through which aqueous humor is drained; and a ripcord inserted into the hollow portion of the tube to control an amount of aqueous humor drainage through the tube. In the implant device, an inner diameter of the tube and a diameter of the ripcord are determined so that pressure formed in the anterior chamber of the eyeball when the tube is inserted into the anterior chamber of the eyeball is within a preset pressure range. The pressure formed in an anterior chamber to an optimal range through an appropriate combination of the tube and the ripcord inserted into the tube.

1. The name of the design product: science popularization interactive instrument (ocular disease simulation). 2. The use of the design product: for science popularization and interaction. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 1. 5. The right view, top view, and bottom view are omitted in the perspective view 1 and perspective view 2. The bottom surface of the design product is a part that is not easily visible or invisible during use, so the top view is omitted.

An insertion device for an ocular implant for regulating intraocular pressure includes a cannula having an internal space for receiving at least a portion of an ocular implant having a stent and an implant opening for inserting the ocular implant; a handle configured to be connected to the cannula and held by a surgeon; and a holder configured to be coupled to the handle and including a receiving portion configured to receive the stent of the ocular implant. The ocular implant insertion device appropriately fixes the stent inserted into the tube of the ocular implant in a manner attached to the insertion device, thereby preventing problems such as the stent coming out of the tube, the implant being separated from the insertion device by the stent, or the stent obscuring the surgeon's field of vision during implant implantation surgery.

The application discloses a fundus photograph classification system based on deep mutual learning. The application fuses two kinds of anomaly detection algorithms of Ganomaly and FastFlow, constructs a detection model which is adaptive and robust to various eye diseases, effectively solves the problem that artificial intelligence cannot be used for intelligent diagnosis of a disease due to the lack of abnormal samples of the disease in practical application, improves the universality and accuracy of the disease detection model, saves the precious time of doctors, and improves the diagnosis efficiency of patients. In addition, the detection method can be applied to a fundus camera, and the device plays a great role in the initial screening stage of eye diseases. With slight cost, the device solves the problem that early eye diseases of patients are difficult to be found due to objective reasons such as insufficient medical resources and lack of experienced doctors, and truly helps community and primary hospitals to realize early discovery, early diagnosis and early treatment, so that the tragedy of blindness caused by delayed treatment due to late discovery is avoided.

The invention relates to the technical field of medicine, in particular to an ophthalmology clinic system and method simulating a three-level diagnosis and treatment mode and medical device.The system comprises a triage module provided with a first diagnosis model and capable of achieving eye disease screening and early triage based on single-mode image data and clinical data of eyes of a user; the diagnosis module is provided with a data fusion model and a second diagnosis module and can realize accurate recognition and disease progress prediction of complex eye diseases, the decision module is provided with a third diagnosis model and can provide personalized eye disease treatment scheme suggestions for patients, and the patients are propagandized and educated in combination with a large language model, so that the diagnosis efficiency is improved. And the clinical decision-making efficiency and the self-management ability of the patient are improved. Therefore, the problems of limited screening capability, low accuracy, incapability of effectively predicting the development trend of diseases and the like due to the fact that ophthalmology diagnosis mostly depends on single image analysis in related technologies are solved.

This invention provides a traditional Chinese medicine composition and its application in the preparation of a topical herbal eye patch for treating thyroid eye diseases, belonging to the field of biomedical technology. The herbal composition consists of *Gynostemma pentaphyllum*, peppermint, *Platycladus orientalis* leaves, borneol, cicada slough, *Astragalus membranaceus*, *Selaginella tamariscina*, *Pteris vittata*, *Scutellaria baicalensis*, apricot leaf, and *Ipomoea aquatica*. Using this herbal composition as raw material, a topical herbal eye patch is prepared. This patch acts directly on acupoints and skin around the eyes, allowing the medicinal properties to penetrate the skin and reach the eye system, achieving the effects of promoting blood circulation, clearing heat and detoxifying, invigorating qi and unblocking meridians, reducing swelling and improving vision. It is suitable for the treatment of thyroid-related eye diseases. This invention's topical herbal eye patch can effectively improve clinical symptoms such as exophthalmos and eye inflammation in patients with thyroid eye diseases, positively impacting their quality of life and effectively improving the clinical treatment efficacy of this disease. The topical herbal eye patch provided by this invention can be further promoted and applied in the clinical treatment of thyroid eye diseases.

The invention provides ophthalmic devices provided with improved blue filtering, mimicking the transmittance of the human ageing eye closer than hitherto possible. The invention furthermore provides methods to obtain such ophthalmic devices, as well as application thereof for prevention or treatment of a degenerative eye disease.

The invention provides antisense oligonucleotide aiming at a Sptbnl target spot and application of the antisense oligonucleotide. The antisense oligonucleotide can be used for knocking down the expression of Sptbnl, and in-vivo and in-vitro experiments find that the antisense oligonucleotide can be used for treating hyperlipidemia and NASH and can also be used for treating neovascular eye diseases.

The present invention relates to a crosslinkable liquid composition for use in a method of treating an eye disease of a subject eye, comprising (i) polyethylene glycol diacrylate (PEGDA), (ii) gelatin or a gelatin-based crosslinkable biomaterial, and (iii) a photoinitiator and optionally a coinitiator, the method comprising applying the crosslinkable liquid composition to the anterior corneal surface of the eye having the eye disease using a mold, crosslinking the crosslinkable liquid composition on the anterior corneal surface of the eye, thereby obtaining a composition crosslinked on the anterior corneal surface of the eye, and correcting the curvature of the crosslinked composition.

The present disclosure provides methods for treating thyroid eye disease, comprising subcutaneously administering a therapeutically effective dose of an anti-interleukin-6 (anti-IL-6) antibody or antibody fragment to a patient in need of treatment. Also provided herein are pharmacologically active agents, compositions, methods, and / or administration schedules for the treatment of thyroid eye disease.

The invention relates to the technical field of cell biology, and particularly discloses an isolated culture method of primary meibomian gland epithelial cells, the obtained primary meibomian gland epithelial cells and application of the primary meibomian gland epithelial cells. The method comprises the following steps: efficiently and mildly digesting meibomian gland tissues by adopting a compound digestive juice consisting of I-type collagenase, dispersing enzyme and trypsin in a specific ratio; stopping digestion by using a serum-containing neutralizing solution and collecting cells; the method comprises the following steps: promoting cell attachment by using a serum-containing initial culture medium, and carrying out selective amplification by using a serum-free proliferation culture medium to finally obtain high-purity and high-activity primary meibomian gland epithelial cells. The method solves the problems of long digestion time, low cell yield, poor purity and the like in the traditional method. The obtained cell can be used for constructing a meibomian gland dysfunction model, screening drugs and researching lipid metabolism, and an important technical platform and a cell model are provided for research and treatment of related eye diseases.

Described herein are modified monoterpene TRPM8 activating compounds. In particular, provided herein are compounds that affect intracellular ion channel function, and are useful as or in conjunction with therapeutic agents. The compounds provided herein are useful in the treatment of a variety of diseases and disorders, including inflammatory eye diseases (e.g., uveitis), cardiovascular diseases, inflammatory diseases, and diseases characterized by aberrant hyperplasia (e.g., cancer).

A method of monitoring an overall thyroid ophthalmopathy treatment includes requesting a user device to take a facial image and enter a questionnaire survey content according to treatment monitoring cycle; obtaining the facial image and the questionnaire survey content from the user device; obtaining, using the facial image and the questionnaire survey content obtained from the user device, a personalized estimate of the user corresponding to exophthalmos information, CAS (Clinical Activity Score) information, and diplopia information among an indicator proven at an approval stage of the medicine; and displaying, which comprises visualizing the personalized estimate of the user in a time-series order from the time the user started administering the medicine on the user device.

The invention discloses a preparation method of a non-Newtonian fluid-based temperature-shear dual response type ophthalmic sustained-release drug carrier, and belongs to the technical field of ophthalmic medicines. The preparation is composed of a dispersed phase (a temperature response type targeting nano-drug carrier) and a continuous phase (a non-Newtonian fluid matrix), wherein the mass fraction of the dispersed phase in the continuous phase is 0.5-2%. The temperature response type targeted nano-drug carrier is of a core-shell two-layer structure, the core is composed of a PLGA-PEG copolymer and an active drug, the shell is formed by grafting poly N-isopropylacrylamide (PNIPAM) and hyaluronic acid, and the lowest critical solution temperature (LCST) of the PNIPAM is 35-37 DEG C; the non-Newtonian fluid matrix is a pseudoplastic fluid, is composed of Carbomer 940 and triethanolamine, and has a shear thinning characteristic. The preparation method comprises the following three steps: preparation of the temperature response type targeting nano-drug carrier, preparation of the non-Newtonian fluid matrix and low-speed dispersion and compounding of the two. According to the invention, shear-response convenient administration, temperature-response precise drug release and long-acting retention synergism are realized, the bioavailability of the drug and the compliance of a patient are remarkably improved, the stability is excellent, the preparation process is simple and controllable, and the preparation method is suitable for long-acting targeted therapy of chronic eye diseases such as allergic conjunctivitis, chronic xerophthalmia, glaucoma and the like.

Methods of treating patients with thyroid eye disease are provided for herein, such as by administering subcutaneously antibodies and compositions that bind to and / or antagonize IGF-1R. 

The invention belongs to the technical field of eye care, and provides vitamin B12-containing contact lens lubricating eye drops and a preparation method thereof, and the vitamin B12-containing contact lens lubricating eye drops comprise 0.5 to 0.7 part of sodium hyaluronate, 0.18 to 0.23 part of a tackifier, 0.3 to 0.35 part of polyvinyl alcohol, 1.1 to 1.2 parts of soybean phospholipid, 0.2 to 0.3 part of sodium cromoglycate, 0.7 to 0.9 part of vitamin B12, 0.005 to 0.01 part of borneol, 0.1 to 0.15 part of a surfactant, 0.1 to 0.18 part of a sodium chloride solution, 0.3 to 0.4 part of tiloxamer and 80 to 90 parts of water. The sodium hyaluronate and the polyvinyl alcohol have moisturizing and thickening effects, the sodium cromoglycate can effectively diminish inflammation and kill viruses, and conjunctivitis and other eye diseases are avoided; vitamin B12 can moisten corneas and relieve eye fatigue. Through cooperative use of the raw materials, the effects of moistening eyes, diminishing inflammation and relieving are achieved.

The present application relates to the technical field of medicine, and provides a lanosterol derivative, a preparation method and application thereof.The structural formula of the lanosterol derivative provided by the present application is shown as formula I or formula II.The lanosterol derivative provided by the present application has both fat solubility and water solubility, can effectively penetrate into the pathological site in the body, and improves the drug utilization degree;the results of examples show that the solubility of the lanosterol derivative provided by the present application in water is obviously higher than that of lanosterol or 25-hydroxy lanosterol, and the lanosterol derivative shows obvious cataract treatment effect in animal body experiments, and has a broad prospect in the preparation of drugs for treating eye diseases or conditions.

Provided are IGF-1R and TSHR binding proteins and pharmaceutical uses thereof. In particular, IGF-1R / TSHR binding proteins, IGF-1R binding proteins, TSHR binding proteins, and methods and related pharmaceutical uses thereof for the treatment of autoimmune diseases (e.g., Graves's eye disease) are provided.